Cargando…
Exosomes and the Future of Immunotherapy in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, associated with a late diagnosis and a five-year survival rate of 8%. Currently available treatments fall short in improving the survival and quality of life of PDAC patients. The only possible curative option is still the surgical re...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387297/ https://www.ncbi.nlm.nih.gov/pubmed/30699928 http://dx.doi.org/10.3390/ijms20030567 |